The active ingredient in Mounjaro and Zepbound. It hits two gut hormone receptors at once (GLP-1 and GIP), making it even more effective than semaglutide for weight loss and blood sugar control. Currently one of the most powerful weight management drugs available.
What to Expect
Week 1–2
Appetite reduction more pronounced than GLP-1-only agonists. Nausea possible during titration. Early satiety. Start at 2.5mg and titrate slowly.
Week 3–6
Significant weight loss acceleration. Improved insulin sensitivity measurable on labs. Reduced cravings. GI side effects diminishing with dose adaptation.
Week 8+
Dramatic weight loss (15-22% of body weight). Improved lipid profiles, HbA1c, and liver enzymes. Potential reversal of hepatic steatosis. Sustained appetite control.
Common Side Effects
Scientific Overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist based on the native GIP sequence with modifications enabling GLP-1R cross-reactivity. The C-20 fatty diacid moiety provides albumin binding for once-weekly dosing. The SURMOUNT-1 trial demonstrated up to 22.5% body weight reduction at 72 weeks (15mg dose). Its dual incretin mechanism produces greater insulin sensitization than GLP-1-only agonists, with additional effects on lipid metabolism and hepatic steatosis. Tirzepatide represents the first clinically validated dual incretin agonist approach.
Dosing
Start at 2.5 mg per week and gradually increase to 5-15 mg per week. Meant for long-term use.
Practical Guide
Reconstitution
Pre-filled pens (Mounjaro/Zepbound) require no reconstitution.
Storage
Unopened: refrigerate. In-use pen: room temperature for up to 21 days. Protect from direct sunlight.
Injection Sites
Subcutaneous injection. Rotate sites weekly. Start at 2.5mg and titrate up every 4 weeks to minimize GI side effects.
Timing
Once weekly on the same day. Any time of day. Allow 4 weeks at each dose level before increasing.
Food
No food timing requirement. Eat smaller meals and avoid high-fat foods that worsen nausea.
Benefit Profile
Medical Considerations
Contraindications
- ✕Personal or family history of medullary thyroid carcinoma
- ✕MEN2 syndrome
- ✕Pregnancy/nursing
- ✕History of pancreatitis
- ✕Severe gastroparesis
Drug Interactions
Recommended Monitoring
- →HbA1c every 3 months
- →Renal function panel
- →Lipase/amylase as needed
- →Heart rate
- →Gallbladder symptoms
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
Tirzepatide for Obesity Treatment and Diabetes Prevention.
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.